latest glp 1 drugs As Interest in GLP-1 Spikes, Employers Weigh the Costs, Benefits GLP-1 Medications: Everything You Need

Over 100 preclinical studies have been published on BPC-157, yet there are zero completed Phase III human clinical trials

Conventional anti-obesity medications are limited to short-term use and have adverse effects, which have contributed to the rise of GLP-1 RAs, e.g., liraglutide, semaglutide, dulaglutide

PMID 11018744

[16] Based on these observations, the potential of glutathione in management of melasma and hyperpigmentation seems plausible

GLP-1 agonists may be preferable in some elderly patients due to lower hypoglycemia risk, though GI side effects and potential for weight loss (which can be undesirable in frail elderly patients) require careful consideration